Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma

Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and combined...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Oncol
Glavni autori: Rizell, Magnus, Sternby Eilard, Malin, Andersson, Mats, Andersson, Bengt, Karlsson-Parra, Alex, Suenaert, Peter
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2019
Teme:
Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6348253/
https://ncbi.nlm.nih.gov/pubmed/30719425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00019
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items